共 50 条
- [46] A MULTICENTER PHASE II RANDOMIZED STUDY OF GEMCITABINE(G) WEEKLY FOLLOWED BY ERLOTINIB(E) AFTER PROGRESSION VERSUS E FOLLOWED BY G AFTER PROGRESSION IN ADVANCED NON SMALL CELL LUNG CANCER(NSCLC)IN VULNERABLE ELDERLY PATIENTS SELECTED WITH A COMPREHENSIVE GERIATRIC ASSESSMENT (CGA) (GFPC*0505) JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1184 - S1184
- [47] First-line Therapy Study of untreated advanced or metastatic Renal Cell Cancer A Phase III Trial of pro-active Therapy Monitoring during the Treatment with Sunitinib or Pembrolizumab in combination with Axitinib or Avelumab in Combination with Axitinib for Patients with advanced or metastatic Renal Cell Cancer (PREPARE) - AUO Study AN 49/18 AKTUELLE UROLOGIE, 2022, 53 (03) : 222 - 225
- [50] A multicenter phase II ranomized study of gemcitabine (G) weekly followed by eriotinib (E) after progression versus E followed by G after progression in advance non-small cell lung cancer (NSCLC) in vulnerable elderly patients selected with a comprehensive geriatric assessment (CGA) (GFPC*0505) JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)